Dacomitinib and Gedatolisib in Combination with Fractionated Radiation in Head and Neck Cancer

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2020 Nov 30

PMID 33251343

Citations 5

Authors

George D Wilson

Thomas G Wilson

Alaa Hanna

Mohamad Dabjan

Katie Buelow

John Torma

Brian Marples

Sandra Galoforo

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: There has been little success targeting individual genes in combination with radiation in head and neck cancer. In this study we investigated whether targeting two key pathways simultaneously might be more effective.

Materials And Methods: We studied the effect of combining dacomitinib (pan-HER, irreversible inhibitor) and gedatolisib (dual PI3K/MTOR inhibitor) with radiation in well characterized, low passage xenograft models of HNSCC in vitro and .

Results: Dacomitinib showed differential growth inhibition in vitro that correlated to EGFR expression whilst gedatolisib was effective in both cell lines. Neither agent radiosensitized the cell lines in vitro. In vivo studies demonstrated that dacomitinib was an effective agent alone and in combination with radiation whilst the addition of gedatolisib did not enhance the effect of these two modalities despite inhibiting phosphorylation of key genes in the PI3K/MTOR pathway.

Conclusions: Our results showed that combining two drugs with radiation provided no added benefit compared to the single most active drug. Dacomitinib deserves more investigation as a radiation sensitizing agent in HNSCC.

Citing Articles

Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets.

Bronhara Pimentel P, Giuliano A, Beczkowski P, Horta R Vet Sci. 2023; 10(6).

PMID: 37368773 PMC: 10302982. DOI: 10.3390/vetsci10060387.

DNA Damage Response Mechanisms in Head and Neck Cancer: Significant Implications for Therapy and Survival.

Papalouka C, Adamaki M, Batsaki P, Zoumpourlis P, Tsintarakis A, Goulielmaki M Int J Mol Sci. 2023; 24(3).

PMID: 36769087 PMC: 9917521. DOI: 10.3390/ijms24032760.

Targeted therapy for head and neck cancer: signaling pathways and clinical studies.

Li Q, Tie Y, Alu A, Ma X, Shi H Signal Transduct Target Ther. 2023; 8(1):31.

PMID: 36646686 PMC: 9842704. DOI: 10.1038/s41392-022-01297-0.

Emerging tyrosine kinase inhibitors for head and neck cancer.

Long Z, Grandis J, Johnson D Expert Opin Emerg Drugs. 2022; 27(3):333-344.

PMID: 36131561 PMC: 9987561. DOI: 10.1080/14728214.2022.2125954.

The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.

Mardanshahi A, Gharibkandi N, Vaseghi S, Abedi S, Molavipordanjani S Mol Biol Rep. 2021; 48(8):1-14.

PMID: 34357550 DOI: 10.1007/s11033-021-06607-3.

References

Stransky N, Egloff A, Tward A, Kostic A, Cibulskis K, Sivachenko A . The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333(6046):1157-60. PMC: 3415217. DOI: 10.1126/science.1208130. View

Gonzales A, Hook K, Althaus I, Ellis P, Trachet E, Delaney A . Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008; 7(7):1880-9. DOI: 10.1158/1535-7163.MCT-07-2232. View

Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G . Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Invest New Drugs. 2015; 33(2):310-20. DOI: 10.1007/s10637-015-0210-1. View

Morris Z, Harari P . Interaction of radiation therapy with molecular targeted agents. J Clin Oncol. 2014; 32(26):2886-93. PMC: 4152717. DOI: 10.1200/JCO.2014.55.1366. View

Huang J, Chunta J, Amin M, Lee D, Grills I, Wong C . Early treatment response monitoring using 2-deoxy-2-[ 18F]fluoro-D-glucose positron emission tomography imaging during fractionated radiotherapy of head neck cancer xenografts. Biomed Res Int. 2014; 2014:598052. PMC: 4022256. DOI: 10.1155/2014/598052. View

Wilson G, Thibodeau B, Fortier L, Pruetz B, Galoforo S, Marples B . Cancer Stem Cell Signaling during Repopulation in Head and Neck Cancer. Stem Cells Int. 2016; 2016:1894782. PMC: 4736761. DOI: 10.1155/2016/1894782. View

Mohan S, Vander Broek R, Shah S, Eytan D, Pierce M, Carlson S . MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015; 21(17):3946-56. PMC: 4558307. DOI: 10.1158/1078-0432.CCR-14-3377. View

Md Anisuzzaman A, Haque A, Wang D, Rahman M, Zhang C, Chen Z . and Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance. Mol Cancer Ther. 2017; 16(4):729-738. DOI: 10.1158/1535-7163.MCT-16-0683. View

Yaromina A, Thames H, Zhou X, Hering S, Eicheler W, Dorfler A . Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol. 2010; 96(1):116-22. DOI: 10.1016/j.radonc.2010.04.020. View

10.

Meyer K, Krueger S, Kane J, Wilson T, Hanna A, Dabjan M . Pulsed Radiation Therapy With Concurrent Cisplatin Results in Superior Tumor Growth Delay in a Head and Neck Squamous Cell Carcinoma Murine Model. Int J Radiat Oncol Biol Phys. 2016; 96(1):161-9. DOI: 10.1016/j.ijrobp.2016.04.031. View

11.

Keysar S, Astling D, Anderson R, Vogler B, Bowles D, Morton J . A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013; 7(4):776-90. PMC: 3760013. DOI: 10.1016/j.molonc.2013.03.004. View

12.

Prawira A, Brana-Garcia I, Spreafico A, Hope A, Waldron J, Abdul Razak A . Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Invest New Drugs. 2016; 34(5):575-83. DOI: 10.1007/s10637-016-0367-2. View

13.

Yaromina A, Zips D, Thames H, Eicheler W, Krause M, Rosner A . Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol. 2006; 81(2):122-9. DOI: 10.1016/j.radonc.2006.08.010. View

14.

Kane J, Krueger S, Hanna A, Raffel T, Wilson G, Madlambayan G . Effect of Irradiation on Tumor Microenvironment and Bone Marrow Cell Migration in a Preclinical Tumor Model. Int J Radiat Oncol Biol Phys. 2016; 96(1):170-8. DOI: 10.1016/j.ijrobp.2016.04.028. View

15.

Kairemo K, Ramsay H, Grenman R . Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997; 529:241-4. DOI: 10.3109/00016489709124133. View

16.

Silva-Oliveira R, Melendez M, Martinho O, Zanon M, de Souza Viana L, Carvalho A . AKT can modulate the response of HNSCC cells to irreversible EGFR inhibitors. Oncotarget. 2017; 8(32):53288-53301. PMC: 5581110. DOI: 10.18632/oncotarget.18395. View

17.

Wallin J, Edgar K, Guan J, Berry M, Prior W, Lee L . GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011; 10(12):2426-36. DOI: 10.1158/1535-7163.MCT-11-0446. View

18.

Ather F, Hamidi H, Fejzo M, Letrent S, Finn R, Kabbinavar F . Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One. 2013; 8(2):e56112. PMC: 3566064. DOI: 10.1371/journal.pone.0056112. View

19.

Gurtner K, Ebert N, Pfitzmann D, Eicheler W, Zips D, Baumann M . Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. Radiat Oncol. 2014; 9:261. PMC: 4271482. DOI: 10.1186/s13014-014-0261-z. View

20.

Baschnagel A, Galoforo S, Thibodeau B, Ahmed S, Nirmal S, Akervall J . Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. Anticancer Res. 2015; 35(11):5973-82. View